TY  - GEN
AU  - Candelaria,M
AU  - Gallardo-Rincón,D
AU  - Arce,C
AU  - Cetina,L
AU  - Aguilar-Ponce,J L
AU  - Arrieta,O
AU  - González-Fierro,A
AU  - Chávez-Blanco,A
AU  - de la Cruz-Hernández,E
AU  - Camargo,M F
AU  - Trejo-Becerril,C
AU  - Pérez-Cárdenas,E
AU  - Pérez-Plasencia,C
AU  - Taja-Chayeb,L
AU  - Wegman-Ostrosky,T
AU  - Revilla-Vazquez,A
AU  - Dueñas-González,A
TI  - A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
SN  - 0923-7534
PY  - 2007///1212
KW  - Adolescent
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - DNA Methylation
KW  - Drug Resistance, Neoplasm
KW  - Epigenesis, Genetic
KW  - Female
KW  - Histone Deacetylases
KW  - metabolism
KW  - Humans
KW  - Hydralazine
KW  - administration & dosage
KW  - Male
KW  - Neoplasms
KW  - drug therapy
KW  - Valproic Acid
N1  - Publication Type: Clinical Trial, Phase II; Journal Article
UR  - https://doi.org/10.1093/annonc/mdm204
ER  -